Loading stock…

Genpact Limited (G) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Genpact Limited

GMarket cap $5.62BPrice $33.5

CountryBermuda

SectorIndustrials

IndustryProfessional Services

Runs data, technology, and AI-driven operations for Fortune 500 giants, handling everything from finance to customer service behind the scenes. Spun off from GE, it now processes billions of transactions yearly for clients who'd rather outsource the grind than build it themselves.

In Bastion Portfolios?

52W Return-14%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+5%5

Revenue Forecast

Rev CAGR (1y)+7%5

Rev CAGR (3y)+7%6

Rev CAGR (5y)+5%5

Earnings Forecast

EPS Growth Y+1+33%9

EPS Growth Y+2+8%6

EPS Growth Y+3+10%6

Quality

Margins

EBIT Margin15%6

Net Income Margin11%6

Free Cash Flow Margin11%6

Debt

Net Debt/EBITDA0.96

Efficiency

ROE22%8

ROA11%9

Earnings Stability55

GEAR+VERY STRONG86

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)810

P/E Ratio (Forward 3y)710

P/BV2.26

EV Multiples

EV/EBITDA Fwd69

EV/EBIT Fwd710

Yield

Free Cash Flow Yield10.2%9

Dividend Yield2.2%6

Momentum

Short term

1 month return-10%2

3 month return+13%9

YTD return-27%2

Mid term

Price vs 52wHigh70%3

1 year return-16%3

Long term

3 year return-2%3

5 year return-25%2

Risk Shield

Price Risk

Beta0.76

Volatility39%5

Free Cash Flow

Free Cash Flow Margin11%6

Free Cash Flow Yield10.2%9

Quality

ROCE19%8

Earnings Stability55

Net Debt/EBITDA0.96

02Growth

Is it actually growing, and how fast?

GGenpact

Revenue FY25$5.1B

GROWTH RATING↗

AVERAGE53 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+7%6

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+33%9

EPS growth, FY27E+8%6

EPS growth, FY28E+10%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 53% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 5%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

GGenpact

Total return Current51.7%

Price return Current37.4%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return+13%9

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-16%3

3-year return-2%3

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+13%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-2% over three years and -25% over five), behind 70% of the market.

It's down 16% over the past year, now 30% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%) and so far this year (-27%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Genpact Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

GGenpact

Revenue FY25$5.1B

GROWTH RATING↗

AVERAGE53 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+5%5

Revenue, next 1Y+7%5

Revenue, next 3Y, CAGR+7%6

Revenue, next 5Y, CAGR+5%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+33%9

EPS growth, FY27E+8%6

EPS growth, FY28E+10%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 10%/yr vs revenue 7%/yr).

WATCH

A mid-pack grower, ahead of 53% of companies worldwide.

Revenue is set to grow 7%/yr over the next 3 years, in line with the market.5/10

Revenue grew 5%/yr over the last 3 years and is set to keep growing around 7%/yr.

Over five years revenue is set to grow 5%/yr, about average versus companies worldwide.5/10

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

GGenpact

Total return Current51.7%

Price return Current37.4%

MOMENTUM RATING↗

WEAK23 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%2

3-month return+13%9

YTD return-27%2

MID & LONG-TERM▾SCORE

% of 52-week high70%3

1-year return-16%3

3-year return-2%3

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over three months (+13%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-2% over three years and -25% over five), behind 70% of the market.

It's down 16% over the past year, now 30% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%) and so far this year (-27%).

BOTTOM LINE

Weak Tape

Returns across short and long horizons rank poorly versus the market. Momentum offers no support here; the case has to come from other factors. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Genpact Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community